Gastric Cancer Therapy Market Size, Share and Growth Outlook, 2026

Gastric Cancer Therapy Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Gastric Cancer Therapy Market size is forecast to increase from $5.86 Billion in 2026 to $15.47 Billion in 2034 at a CAGR of 12.9% between 2026 and 2034.

The Gastric Cancer Therapy market report provides detailed analysis and outlook of Gastric Cancer Therapy segments including By Therapy Type (Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy, Surgery, Combination Therapy), By Drug Class (Monoclonal Antibodies, Small Molecule Inhibitors, Antibody–Drug Conjugates, PD-1), By Disease Stage (Early-Stage, Resectable, Unresectable Locally Advanced, Advanced ), By Route of Administration (Intravenous, Oral), By End-User (Hospitals and Oncology Centers, Cancer Research Institutes, Specialty Clinics) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Gastric Cancer Therapy Industry Overview

Immunotherapy and Precision Medicine Transform Gastric Cancer Treatment

The gastric cancer therapy industry is undergoing significant transformation as immunotherapy, targeted therapies, and genomic research reshape treatment strategies for both early-stage and advanced disease. Healthcare providers are increasingly adopting biomarker-driven approaches that enable personalized treatment selection and improved clinical outcomes. Advances in perioperative therapies, molecular profiling, and precision oncology are expanding therapeutic options for patients with gastric and gastroesophageal junction cancers while supporting more individualized care pathways.

Perioperative Immunotherapy Establishes a New Treatment Standard

A major advancement in the gastric cancer therapy market emerged with the European Commission’s approval of durvalumab (Imfinzi) in combination with perioperative FLOT chemotherapy for patients with resectable Stage II–IVA gastric and gastroesophageal junction cancers. The approval was supported by findings from the Phase III MATTERHORN trial and marked the introduction of the first perioperative immunotherapy regimen for this patient population. The integration of immunotherapy into perioperative treatment protocols reflects the growing role of immune-based approaches in improving disease management and supporting long-term treatment outcomes in gastric cancer care.

Biomarker-Driven Therapies Expand Precision Oncology Opportunities

Targeted therapies directed at specific molecular biomarkers are becoming increasingly important within the gastric cancer treatment landscape. Data presented at the 2026 ASCO GI Cancers Symposium highlighted promising outcomes for CLDN18.2-targeted therapeutic strategies. Results from the ILUSTRO trial demonstrated that zolbetuximab combined with chemotherapy and nivolumab significantly improved progression-free survival among patients with locally advanced or metastatic gastric cancer expressing the CLDN18.2 biomarker. These developments underscore the growing importance of molecular testing and biomarker-guided treatment selection in advancing precision oncology for gastric malignancies.

Expanding Genomic Databases Accelerate Therapeutic Discovery

Comprehensive genomic research is strengthening the foundation for future gastric cancer therapies. Stanford University’s Gastric Cancer Registry expanded its Genome Explorer portal to include integrated genomic datasets from hundreds of gastric and esophageal tumor samples. The enhanced repository supports multidisciplinary research initiatives focused on identifying novel therapeutic targets, understanding molecular drivers of tumor progression, and advancing personalized treatment development. Growing access to large-scale genomic datasets is expected to accelerate innovation in targeted therapies and improve understanding of gastric cancer biology across the global oncology community.

Gastric Cancer Therapy Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Gastric Cancer Therapy market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Eli Lilly and Company, Bristol-Myers Squibb, Merck & Co. (MSD), Roche (Genentech), AstraZeneca, Novartis AG, Pfizer Inc., Daiichi Sankyo, Ono Pharmaceutical, Amgen Inc.. The Gastric Cancer Therapy market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Gastric Cancer Therapy industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Gastric Cancer Therapy Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Gastric Cancer Therapy companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Gastric Cancer Therapy markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Gastric Cancer Therapy Market Competitive Benchmarking and Company Analysis

Leading companies in Gastric Cancer Therapy industry include- Eli Lilly and Company, Bristol-Myers Squibb, Merck & Co. (MSD), Roche (Genentech), AstraZeneca, Novartis AG, Pfizer Inc., Daiichi Sankyo, Ono Pharmaceutical, Amgen Inc.. The Gastric Cancer Therapy market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Gastric Cancer Therapy Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Gastric Cancer Therapy market remains one of the strongest-performing segments in the country.
The US Gastric Cancer Therapy Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Gastric Cancer Therapy market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Gastric Cancer Therapy industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Gastric Cancer Therapy markets

Canada's strong Gastric Cancer Therapy sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Gastric Cancer Therapy market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Gastric Cancer Therapy Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Gastric Cancer Therapy market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Gastric Cancer Therapy population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Gastric Cancer Therapy industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Gastric Cancer Therapy market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Gastric Cancer Therapy sales through 2034

France Gastric Cancer Therapy companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Gastric Cancer Therapy Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Gastric Cancer Therapy distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Gastric Cancer Therapy Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Gastric Cancer Therapy market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Gastric Cancer Therapy industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Gastric Cancer Therapy industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Gastric Cancer Therapy Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Gastric Cancer Therapy market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Gastric Cancer Therapy market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Gastric Cancer Therapy Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Gastric Cancer Therapy Market Segmentation

By Therapy Type
Targeted Therapy
Immunotherapy
Chemotherapy
Radiation Therapy
Surgery
Combination Therapy
By Drug Class
Monoclonal Antibodies
Small Molecule Inhibitors
Antibody–Drug Conjugates
PD-1
By Disease Stage
Early-Stage
Resectable
Unresectable Locally Advanced
Advanced
By Route of Administration
Intravenous
Oral
By End-User
Hospitals and Oncology Centers
Cancer Research Institutes
Specialty Clinics

Top Companies in Gastric Cancer Therapy Industry

Eli Lilly and Company
Bristol-Myers Squibb
Merck & Co. (MSD)
Roche (Genentech)
AstraZeneca
Novartis AG
Pfizer Inc.
Daiichi Sankyo
Ono Pharmaceutical
Amgen Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025